Fig. 3

Key residues of HLA-B*13 family members are involved in DDS presentation and CTLs-mediated activation. A the difference between HLA-B*13:01 and HLA-B*13:02 in amino acid sequence. B the difference between HLA-B*13:01 and HLA-B*13:02 in structure. 121R of HLA-B*13:01 and 121T of HLA-B*13:02 with DDS complex are shown as stick and electrostatic surface representation, respectively. C the IFN-γ releases of CTLs expanded from DDS-induced DIHS patients against DDS and C1R B transfectants expressing different HLA-B*13:01 wild type or single-site mutants. D the IFN-γ releases of CTLs against DDS and C1R B transfectants expressing different HLA-B*13:01 wild type, HLA-B*13:02 wild type, or two single-site mutants of HLA-B*13:01. E the IFN-γ releases of CTL against DDS and C1R B transfectants expressing different HLA-B*13:01 wild type, HLA-B*13:02 wild type, or single-site mutants of HLA-B*13:02. F the IFN-γ releases of CTL against DDS and C1R B transfectants expressing different HLA-B*13:01 wild type, HLA-B*13:02 wild type, or two single-site mutants of HLA-B*13:02. The entire experiment was repeated thrice and values are mean standard error of the mean. *P < 0.01; **P < 0.05; ***P < 0.001, by two-tailed Student t test